You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Contributor:
Tikkanen, Ilkka;
Narko, Kirsi;
Zeller, Cordula;
Green, Alexandra;
Salsali, Afshin;
Broedl, Uli C.;
Woerle, Hans J.
imprint:
American Diabetes Association, 2015
Published in:Diabetes Care
Language:
English
DOI:
10.2337/dc14-1096
ISSN:
1935-5548;
0149-5992
Origination:
Footnote:
Description:
<jats:sec>
<jats:title>OBJECTIVE</jats:title>
<jats:p>To investigate the efficacy, safety, and tolerability of empagliflozin in patients with type 2 diabetes and hypertension.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>RESEARCH DESIGN AND METHODS</jats:title>
<jats:p>Patients (N = 825) with type 2 diabetes and hypertension (mean seated systolic blood pressure [SBP] 130–159 mmHg and diastolic blood pressure [DBP] 80–99 mmHg) were randomized (double blind) to 10 mg or 25 mg empagliflozin or placebo once daily for 12 weeks.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>RESULTS</jats:title>
<jats:p>At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h SBP (ambulatory blood pressure monitoring [ABPM]) was −3.44 mmHg (95% CI −4.78, −2.09) with 10 mg empagliflozin and −4.16 mmHg (−5.50, −2.83) with 25 mg empagliflozin (both P &lt; 0.001). At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h DBP (ABPM) was −1.36 mmHg (95% CI −2.15, −0.56) with 10 mg empagliflozin and −1.72 mmHg (95% CI −2.51, −0.93) with 25 mg empagliflozin (both P &lt; 0.001). Changes in office BP were consistent with ABPM. Adjusted mean difference versus placebo in change from baseline in HbA1c at week 12 was −0.62% (95% CI −0.72, −0.52) (−6.8 mmol/mol [95% CI −7.9, −5.7]) with 10 mg empagliflozin and −0.65% (95% CI −0.75, −0.55) (−7.1 mmol/mol [95% CI −8.2, −6.0]) with 25 mg empagliflozin (both P &lt; 0.001). Empagliflozin was well tolerated. One patient on placebo and one patient on 10 mg empagliflozin reported events consistent with volume depletion.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>CONCLUSIONS</jats:title>
<jats:p>Empagliflozin was associated with significant and clinically meaningful reductions in BP and HbA1c versus placebo and was well tolerated in patients with type 2 diabetes and hypertension.</jats:p>
</jats:sec>